Friday, 20 Jul 2018

You are here

Highlights from EULAR 2017 - From RheumReports.com

The following are my favorite and least favorite presentations and abstracts from EULAR 2017. This originally appeared on RheumReports.com, a great Rheumatology website run by Dr. Andy Thomspon.

  1. Vobarilizumb is a nanobody that inhibits IL-6, but failed in MTX-IR RA trials (there were country differences with respect to placebo response which may or may not have affected the outcome of the study). (Dorner T, et al, OP098)
  2. Ongoing infection safety of JAK-inhibitors (baricitinib meta-analysis of phase III trial results adds to tofacitinib and TNFi and non-TNFi biologics) – all will similar serious infection rates. (Strand V, et al, THU0211)
  3. Doesn’t matter (in RA) what target you use, just use it to get more patients into remission/low disease state. Favorite targets are CDAI, SDAI, DAS28, RAPIDs3, Boolean remission, ultrasound remission, etc. (numerous abstracts)
  4. All ANCAs are not created equally – they have post translational changes that may be important for prognosis, flaring, etc. (Luqmani R, et al. SP0132)
  5. Certrolizumab pegol does not cross the placenta and should be safe in women needing treatment while pregnant. (Mariette X, et al, OP0017)
  6. IL-18 is in the IL-1 family. Tadekinig alpha is a recombinant IL-18 protein binding inhibitor that seemed to help patients with adult onset Still’s disease who were recalcitrant to previous treatment, in an open label phase II trial. (Gabay C, et al, FRI0582).
  7. In giant cell arteritis, MTX can prevent relapses compared to patients not on MTX. (D Frietes, et al, THU0309) and the dose of tocilizumab in GCA is likely more optimal as TCZ 162 mg sc weekly. (Stone J, et al OP0131)
  8. Lots of early and later phase trials in SLE with varied mechanisms (atacicept [BLyS and APRIL with B cell signalling changes,] drugs affecting plasma cells, CC2, ICOS, gamma interferon reduction, calcineurin inhibitor the latter in SLE nephritis had more deaths when added to MMF than MMF alone). More to come I assume.
  9. Stop doing IL-1 inhibition in OA, the studies all fail as did one presented at EULAR.
  10. Retention and response (EULAR good response) is better of non-TNFi biologics in RA is better than TNFi as the first biologic (Swedish register). (Frisell T, FRI0213)
  11. Oral strategy study (Fleischmann R, et al. Lancet 2017) in MTX-IR showed that MTX adding either tofacitinib or adalimumab were not inferior to each other, but stopping MTX and switching to tofacitinib has inconclusive results (not non-inferior but can’t say inferior, but numerically is a bit less).
  12. Rituximab with belimumab helped severe refractory SLE (open label severe SLE). (Krasji T et al SAT0258, OP0302)
  13. Cyclophoshamide did not prolong survival in follow up of sleroderma lung study (Volkmann ER, et al, OP0124)

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Cocoon Therapy? (7.20.18)

Dr. Jack Cush reviews highlights from the news and social media on RheumNow.com in the past week. 

Proposed Changes for 2019 Medicare Fee Schedule

On July 12th the Centers for Medicare & Medicaid Services (CMS) released its proposed rule changes for the 2019 Medicare physician fee schedule.  This year, CMS has combined the Medicare physician fee schedule proposed rule with recommendations for the Quality Payment Program (QPP), which will be officially published in the Federal Register on July 27.

Trend Towards Fewer Self-Employed Physicians

 

A nationwide survey study analyzed healthcare provider (HCP) employment type (self-employed, employed by private sector, or employed by government) and annual labor earnings (2001 to 2015) and found that the health care landscape is changing with few self-employed practitioners and more being larger organizations. 

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.